×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVRO – nevro corp. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVRO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
08:22 am
nvro
Cellino Hosts Second Annual Personalized RegenMed Forum to Accelerate Progress in Regenerative Medicine [Yahoo! Finance]
Low
Report
Cellino Hosts Second Annual Personalized RegenMed Forum to Accelerate Progress in Regenerative Medicine [Yahoo! Finance]
11/20
12:04 am
nvro
Nevro Corp. (NYSE: NVRO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Nevro Corp. (NYSE: NVRO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/19
10:51 am
nvro
NVRO Stock Declines Despite Positive Study Data of Nevro1 System [Yahoo! Finance]
Low
Report
NVRO Stock Declines Despite Positive Study Data of Nevro1 System [Yahoo! Finance]
11/18
08:35 am
nvro
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches [Yahoo! Finance]
Medium
Report
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches [Yahoo! Finance]
11/18
08:30 am
nvro
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
Medium
Report
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
11/15
09:53 am
nvro
Nevro Stock May Gain on the CE Mark Certification for HFX iQ [Yahoo! Finance]
High
Report
Nevro Stock May Gain on the CE Mark Certification for HFX iQ [Yahoo! Finance]
11/15
08:30 am
nvro
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
High
Report
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
11/14
06:59 am
nvro
Analysts Are Updating Their Nevro Corp. (NYSE:NVRO) Estimates After Its Third-Quarter Results [Yahoo! Finance]
Medium
Report
Analysts Are Updating Their Nevro Corp. (NYSE:NVRO) Estimates After Its Third-Quarter Results [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
11/12
10:45 am
Reiterates
Sector Perform
Sector Perform
Royal Bank of Canada
High
Report
-11.4%
11/12
10:45 am
Reiterates
Sector Perform
Sector Perform
Royal Bank of Canada
High
Report
-11.4%
Date
Time
Symbol
Headline
Impact
11/14
05:32 pm
nvro
Form SC 13D/A NEVRO CORP Filed by: Engaged Capital LLC
High
Report
Form SC 13D/A NEVRO CORP Filed by: Engaged Capital LLC
11/14
05:19 pm
nvro
Form SC 13G/A NEVRO CORP Filed by: ARMISTICE CAPITAL, LLC
High
Report
Form SC 13G/A NEVRO CORP Filed by: ARMISTICE CAPITAL, LLC
11/14
04:12 pm
nvro
Form 8-K NEVRO CORP For: Nov 11
High
Report
Form 8-K NEVRO CORP For: Nov 11
11/12
09:28 am
nvro
Form 10-Q NEVRO CORP For: Sep 30
High
Report
Form 10-Q NEVRO CORP For: Sep 30
11/8
02:20 pm
nvro
Form SC 13G/A NEVRO CORP Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G/A NEVRO CORP Filed by: BlackRock, Inc.
10/28
04:06 pm
nvro
Form 4 NEVRO CORP For: Oct 24 Filed by: Thornal Kevin R
Medium
Report
Form 4 NEVRO CORP For: Oct 24 Filed by: Thornal Kevin R
10/22
03:24 pm
nvro
Form SC 13G/A NEVRO CORP Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A NEVRO CORP Filed by: BlackRock, Inc.
10/8
05:32 pm
nvro
Form 4 NEVRO CORP For: Oct 04 Filed by: Rashid Kashif
Neutral
Report
Form 4 NEVRO CORP For: Oct 04 Filed by: Rashid Kashif
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/6
Q3/2019 9/30/2019 EPS -0.580 ZacksConsensus -0.810 ActVsEst 0.230 - Beat
21.3%
8/9 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at Canaccord Genuity from $50.00 to $59.00. They now have a "hold" rating on the stock. 17.8%
5/10 Nevro Corp (NYSE: NVRO) had its price target lowered by analysts at JMP Securities from $80.00 to $70.00. They now have a "market outperform" rating on the stock. 15.8%
4/1 Nevro sees Q1 revenue of almost $87M; shares up 2% after hours [Seeking Alpha] 11.3%
4/3 Nevro Announces the Full Exercise of the Underwriter's Option to Purchase Additional Common Stock and the Underwriter's Over-allotment Option to Purchase Additional Convertible Senior Notes 10.2%
1/27 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at JMP Securities to $150.00. They now have an "outperform" rating on the stock. 7.1%
8/10 Nevro Corp (NVRO) Q2 2019 Earnings Call Transcript [The Motley Fool] 6.7%
2/25 Form 8-K NEVRO CORP For: Feb 25 5.6%
1/15 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at UBS Group AG from $77.00 to $84.00. They now have a "sell" rating on the stock. 3.5%
10/2 Form 4 NEVRO CORP For: Sep 30 Filed by: Vale Brad 3.2%
8/9 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at Canaccord Genuity from $50.00 to $59.00. They now have a "hold" rating on the stock. 17.8%
5/10 Nevro Corp (NYSE: NVRO) had its price target lowered by analysts at JMP Securities from $80.00 to $70.00. They now have a "market outperform" rating on the stock. 15.8%
4/1 Nevro sees Q1 revenue of almost $87M; shares up 2% after hours [Seeking Alpha] 11.3%
4/3 Nevro Announces the Full Exercise of the Underwriter's Option to Purchase Additional Common Stock and the Underwriter's Over-allotment Option to Purchase Additional Convertible Senior Notes 10.2%
1/27 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at JMP Securities to $150.00. They now have an "outperform" rating on the stock. 7.1%
8/10 Nevro Corp (NVRO) Q2 2019 Earnings Call Transcript [The Motley Fool] 6.7%
2/25 Form 8-K NEVRO CORP For: Feb 25 5.6%
1/15 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at UBS Group AG from $77.00 to $84.00. They now have a "sell" rating on the stock. 3.5%
10/2 Form 4 NEVRO CORP For: Sep 30 Filed by: Vale Brad 3.2%
TOP News Decliners
4/13
Sangamo And Biogen Tie Up, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
-6.9%
3/27 Form SC 13G NEVRO CORP Filed by: HealthCor Management, L.P. -6.3%
10/22 Nevro Corp (NYSE: NVRO) is now covered by analysts at Oppenheimer Holdings Inc.. They set a "market perform" rating on the stock. -4.2%
5/9 Q1/2019 3/31/2019 EPS -1.450 ZacksConsensus -0.660 ActVsEst (0.790) - Miss -4.1%
11/7 Edited Transcript of NVRO earnings conference call or presentation 6-Nov-19 9:30pm GMT [Yahoo! Finance News] -4.1%
2/28 Form 8-K NEVRO CORP For: Feb 27 -4.0%
2/26 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at Leerink Swann from $146.00 to $158.00. They now have a "positive" rating on the stock. -3.5%
8/23 Nevro to Present at Morgan Stanley 17th Annual Healthcare Conference -3.2%
4/21 Nevro to Report First Quarter 2020 Financial Results -2.7%
4/14 Form 4 NEVRO CORP For: Apr 12 Filed by: GROSSMAN D KEITH -2.7%
3/27 Form SC 13G NEVRO CORP Filed by: HealthCor Management, L.P. -6.3%
10/22 Nevro Corp (NYSE: NVRO) is now covered by analysts at Oppenheimer Holdings Inc.. They set a "market perform" rating on the stock. -4.2%
5/9 Q1/2019 3/31/2019 EPS -1.450 ZacksConsensus -0.660 ActVsEst (0.790) - Miss -4.1%
11/7 Edited Transcript of NVRO earnings conference call or presentation 6-Nov-19 9:30pm GMT [Yahoo! Finance News] -4.1%
2/28 Form 8-K NEVRO CORP For: Feb 27 -4.0%
2/26 Nevro Corp (NYSE: NVRO) had its price target raised by analysts at Leerink Swann from $146.00 to $158.00. They now have a "positive" rating on the stock. -3.5%
8/23 Nevro to Present at Morgan Stanley 17th Annual Healthcare Conference -3.2%
4/21 Nevro to Report First Quarter 2020 Financial Results -2.7%
4/14 Form 4 NEVRO CORP For: Apr 12 Filed by: GROSSMAN D KEITH -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: